NAVB Stock - Navidea Biopharmaceuticals, Inc.
Unlock GoAI Insights for NAVB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $65,652 | $531,513 | $915,013 | $26,618 | $322,521 |
| Gross Profit | $-170,302 | $332,679 | $913,965 | $19,951 | $225,885 |
| Gross Margin | -259.4% | 62.6% | 99.9% | 75.0% | 70.0% |
| Operating Income | $-14,050,895 | $-12,060,412 | $-10,711,181 | $-10,962,517 | $-10,847,301 |
| Net Income | $-15,177,153 | $-11,730,931 | $-10,721,691 | $-10,945,549 | $-16,126,437 |
| Net Margin | -23117.6% | -2207.1% | -1171.8% | -41120.9% | -5000.1% |
| EPS | $-0.59 | $-0.40 | $-0.48 | $-0.76 | $-1.89 |
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Visit WebsiteEarnings History & Surprises
NAVBEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 4, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Dec 18, 2024 | — | — | — | — |
Q3 2024 | Sep 27, 2024 | — | — | — | — |
Q2 2024 | Jun 27, 2024 | — | — | — | — |
Q1 2024 | Mar 19, 2024 | — | — | — | — |
Q4 2023 | Nov 14, 2023 | — | $-0.02 | — | — |
Q3 2023 | Aug 11, 2023 | — | $-0.03 | — | — |
Q2 2023 | May 11, 2023 | — | $-0.05 | — | — |
Q1 2023 | Mar 21, 2023 | — | $-0.11 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-0.25 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-0.10 | — | — |
Q2 2022 | May 12, 2022 | — | $-0.10 | — | — |
Q1 2022 | Mar 23, 2022 | $-0.03 | $-0.12 | -300.0% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.11 | $-0.08 | +27.3% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.09 | $-0.09 | 0.0% | = MET |
Q2 2021 | May 11, 2021 | $-0.08 | $-0.11 | -37.5% | ✗ MISS |
Q1 2021 | Mar 24, 2021 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q4 2020 | Nov 12, 2020 | $-0.08 | $-0.13 | -62.5% | ✗ MISS |
Latest News
Frequently Asked Questions about NAVB
What is NAVB's current stock price?
What is the analyst price target for NAVB?
What sector is Navidea Biopharmaceuticals, Inc. in?
What is NAVB's market cap?
Does NAVB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NAVB for comparison